Hyperprogressive Disease After Combined Anti-PD-L1 and Anti-CTLA-4 Immunotherapy for MSI-H/dMMR Gastric Cancer: A Case Report.
Front Oncol. 2021 Sep 24;11:756365. doi: 10.3389/fonc.2021.756365. eCollection 2021.
Front Oncol. 2021.
PMID: 34631593
Free PMC article.